Clinical Trial Search

Primary: Number of Participants With Unacceptable Toxicity — 0; 0; 0; 0 participants

Primary: Event-free Survival (EFS) — 74; 77; 55; 53 Percentage EFS — p=0.214

Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months

Primary: Percentage of Participants With Tumor Response — 3.1; 0; 3.1; 15.6 percentage of participants

Primary: Bone Density (Low Areal Bone Mineral Density (aBMD)) — -1.3; -0.9; -2.4; -1.2 z-score

Primary: Tumor Response — 10 participants

Primary: Disease Control Rate (Cohort I) — 1 participants

Primary: Status of FAS Ligand in Pre-chemotherapy Sample — 7; 5; 1; 1 participants

Primary: Change in Urinary Biomarkers of Acute Kidney Injury (AKI) Between Pre-Treatment (Baseline), After CISplatin (C) Treatments, and After HDTMX Treatments — 1.7; 1.7; 2.1…

Primary: Disease Control Success — 3 Participants

Primary: Radiographic Response — 21; 5; 5; 3 participants

Primary: Objective Response Rate — 6; 5; 14 participants

Primary: Maximum Tolerated Dose (MTD) of Ra-223 Dichloride in Osteosarcoma — 100; 100 kBq/kg

Primary: Response Rate — 0 percentage of participants

Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years

Primary: Limiting Toxicity — 1; 1; 3; 2 participants

Primary: Number of Participants With Engraftment — 23 Participants

Primary: T2* Relaxation Time of Bone Sarcomas and Osteomyelitis Subjects — 7.3; 7.7 milliseconds

Primary: Percentage of Participants With Overall Tumor Response (Response Rate) — 0; 0; 0; 0 Percentage of Participants

Primary: Disease Control Success — 0 participants

Primary: Disease Control — 11 Participants

Primary: Best Anatomical Tumor Response — 0; 2; 22; 30 participants

Primary: Part 2: Radiologic Progression-free Survival (PFS) — 18.7; 24.1 weeks — p== 0.6562

Primary: Lesion-specific Local Control at 6 Months Post-SBRT as Assessed by Percentage of Lesions Locally Controlled — 95 percentage of lesions

Primary: The Study Medication Was to be Considered Effective if the Population Response Rate Was Found to be Greater Than 20% and Individuals Who Demonstrated a CR or PR or Whose…

Primary: Dose Escalation Part: Number of Dose-Limiting Toxicities (DLTs) at Each Dose Level on Cycle 1 — 0; 2 Number of DLTs

Primary: Progression-free Survival (PFS) by Independent Imaging Review (IIR) Assessment — 6.5; 5.5 months — p=0.0396

Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events

Primary: Number of Participants With Grade 3 Bilirubin — 3 participants with Grade 3 Bilirubin

Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 1; 1; 0; 1 Participants